Supernus Pharmaceuticals (SUPN) On Chloe Kim ADHD Push And Whether Undervalued Looks Priced In
Olympic snowboarder Chloe Kim’s new awareness partnership with Supernus Pharmaceuticals (SUPN) puts extra focus on Qelbree and adult ADHD and may lead some investors to recheck how the stock’s current pricing reflects its ADHD portfolio.
Supernus Pharmaceuticals’ stock is trading at US$44.21, with the 1-day share price return of 1.10% partially offsetting a weaker year to date share price return that is down 10.63%. The 5-year total shareholder return of 61% points to a much stronger longer term record and suggests recent momentum has faded even as new ADHD related visibility emerges from the Chloe Kim campaign.
Scan how Supernus Pharmaceuticals compares with other CNS and ADHD focused companies by checking out a curated set of 19 high quality undiscovered gems that the broader market may be overlooking.
For Supernus Pharmaceuticals, the recent share pullback alongside solid reported revenue and net income growth raises a core issue. Are investors reassessing the business, or is sentiment drifting away from the underlying ADHD and CNS portfolio value?
Most Popular Narrative: 29.6% Undervalued
At a last close of $44.21 versus a narrative fair value of $62.83, Supernus Pharmaceuticals is being framed as materially undervalued on a discounted cash flow basis using a 7.108% discount rate.
Expanding patient pool for core products, Qelbree and GOCOVRI, driven by increased prevalence and diagnosis of CNS disorders, as well as broader healthcare access (especially among Medicare patients, as seen with GOCOVRI’s prescription growth), is likely to sustain robust top-line revenue growth.
Commercial infrastructure and recent launch of ONAPGO position Supernus to capture further market share in Parkinson’s disease, benefiting from demographic aging and rising CNS disease burden, which should materially boost revenue and improve gross margins as fixed costs are leveraged.
Want to understand why this narrative supports a higher value for Supernus Pharmaceuticals? The case hinges on faster revenue expansion, rising margins, and a richer profit multiple than the broader pharmaceuticals sector. The details behind those projections are where the story really get interesting.
According to the most followed narrative, analysts group a few key inputs behind that $62.83 fair value. They factor in revenue growth ahead of the wider US market, a shift from current losses to positive net margins, and a future earnings profile that would support a higher P/E multiple than the broader pharmaceuticals industry today. Those assumptions are then discounted back using a 7.108% rate to arrive at a present value that sits well above the current $44.21 share price.
Result: Fair Value of $62.83 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors in Supernus Pharmaceuticals still need to weigh pricing pressure on key ADHD and Parkinson’s drugs, as well as the heavy reliance on a small group of products.
Find out about the key risks to this Supernus Pharmaceuticals narrative.
Next Steps
If this Supernus Pharmaceuticals story sounds optimistic, do not wait around for someone else to decide what it means. Take a closer look at the data and see how the 3 key rewards aligns with your own assessment.
Looking For More Investment Ideas Beyond Supernus Pharmaceuticals?
If you stop with Supernus Pharmaceuticals, you risk missing other compelling stocks. Use the Simply Wall St Screener to broaden your opportunity set intelligently.
- Spot potential mispricing by running through a curated 45 high quality undervalued stocks that may offer stronger upside according to their fundamentals.
- Strengthen your downside protection by checking companies in the 74 resilient stocks with low risk scores that score well on financial resilience.
- Upgrade portfolio quality by scanning the list of solid balance sheet and fundamentals (52 results) to find businesses supported by healthier balance sheets and fundamentals.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com